YATHARTHNSE27 January 2025

Yatharth Hospital & Trauma Care Services Limited has informed the Exchange about Investor Presentation

Yatharth Hospital & Trauma Care Services Limited

January 27, 2025

The Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (E) Mumbai – 400 051

Dept. of Listing Operations BSE Limited, P J Towers, Dalal Street, Mumbai -400001, India

Symbol: YATHARTH

Scrip Code: 543950

Dear Sir/Ma’am,

Sub:- Investor's presentation- Q3FY25 Results.

Please find enclosed Investor's Presentation for Q3FY25 Results pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015.

Kindly take the same in your records.

Thanking you,

Your faithfully, For Yatharth Hospital and Trauma Care Services Limited

Ritesh Mishra Company Secretary & Compliance Officer Enclosed: As above

Q3 & 9M FY25 Earnings Presentation Jan 27, 2025

Disclaimer

Certain matters discussed in this Presentation may contain statements regarding the company’s market opportunity and business

prospects that are individually and collectively forward-looking statements. Such forward-looking statements doesn’t guarantee

future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These

risks and uncertainties include, but are not limited to, the performance of the economy, industry, competition, the company’s

ability to successfully implement its strategy, technological implementation, changes and advancements, the company’s market

preferences and its exposure to market risks, as well as other risks. The company’s actual results, levels of activity, performance or

achievements could differ materially and adversely from results expressed in or implied by this presentation. The company

assumes no obligation to update any forward-looking information contained in this presentation. Any forward-looking statements

and projections made by third parties included in this presentation are not adopted by the company and the company is not

responsible for such third-party statements and projections. You are cautioned not to place undue reliance on these forward-

looking statements, which are based on the current view of the management of the Company on future events.

Q3 & 9M FY25 Performance Highlights

9M FY25 Performance Summary

Bed Capacity*

2,300+ beds

EBITDA Margin

25.2% -192bps YoY

Occupancy

61% +7% YoY

Revenue

Rs. 6,487 mn +32% YoY

PAT

Rs. 918 mn +21% YoY

ARPOB

Rs. 30,614 +8% YoY

EBITDA

Rs. 1,632 mn +22% YoY

PAT Margin

14.2% -130bps YoY

ALOS

4.38

* 1,605 beds, excluding upcoming hospitals in Delhi & Faridabad

Q3 FY25 Performance Summary

Revenue

Rs. 2,192 mn +31% YoY

PAT

Rs. 305 mn +3% YoY

Occupancy

60% +8% YoY

EBITDA

Rs. 549 mn +18% YoY

PAT Margin

13.9% -377bps YoY

ARPOB

Rs. 30,652 +4% YoY

EBITDA Margin

25.1% -277bps YoY

Net Cash

Rs. 5,605 mn

ALOS

4.30

Robust Improvement in Financial Parameters

Revenue (Rs mn)

EBITDA (Rs mn) & EBITDA%

+31% YoY

+1% QoQ

1,668

1,778

2,118

2,178

2,192

Q3FY24

Q4FY24

Q1FY25

Q2FY25

Q3FY25

Finance Cost (Rs mn)

27.8%

26.2%

25.3%

25.1%

464

465

537

546

549

Q3FY24

Q4FY24

Q1FY25

Q2FY25

Q3FY25

PAT (Rs mn) & PAT%

17.7%

21.6%

14.3%

14.2%

13.9%

295

383

304

310

305

80 0 795 790 785 780 775 770 765 760 755 750 745 740 735 730 725 720 715 710 705 700 69 5 69 0 68 5 68 0 675 670 66 5 66 0 65 5 65 0 64 5 64 0 635 630 625 620 615 610 60 5 60 0 59 5 59 0 58 5 58 0 575 570 56 5 56 0 55 5 55 0 54 5 54 0 535 530 525 520 515 510 50 5 50 0 49 5 49 0 48 5 48 0 475 470 46 5 46 0 45 5 45 0 44 5 44 0 435 430 425 420 415 410 40 5 40 0 395 390 385 380 375 370 365 360 355 350 345 340 335 330 325 320 315 310 305 300 295 290 285 280 275 270 265 260 255 250 245 240 235 230 225 220 215 210 205 200 195 190 185 180 175 170 165 160 155 150 145 140 135 130 125 120 115 110 105 100 95 90 85 80 75 70 65 60 55 50 45 40 35 30 25 20 15 10 5 0

Q3FY24

Q4FY24

Q1FY25

Q2FY25

Q3FY25

Q3FY24

Q4FY24

Q1FY25

Q2FY25

Q3FY25

30.0%

29.0%

28.0%

27.0%

26.0%

25.0%

24.0%

23.0 %

22.0 %

21.0%

20.0%

19.0%

18.0%

17.0%

16.0%

15.0%

14.0%

13.0 %

12.0%

11.0%

10.0%

9.0%

8.0%

7.0 %

6.0%

5.0%

4.0%

3.0%

2.0%

1.0 %

0.0%

27%

26%

25%

24%

23%

22%

21%

20%

19%

18%

17%

16%

15%

14%

13%

12%

11%

10%

Healthy performances across operational metrics

IPD & OPD Volumes (in ‘000s)

Occupancy (%)

IPD Volume

OPD Volume

102

116

109

61%

60%

57%

52%

Q3FY24

Q4FY24

Q1FY25

Q2FY25

Q3FY25

Q3FY24

Q4FY24

Q1FY25

Q2FY25

Q3FY25

IPD & OPD Revenue (Rs mn)

IPD Revenue

OPD Revenue

1,668

192

1,477

200 0

150 0

100 0

500

1,778

216

1,562

2,118

236

2,178

270

2,192

249

1,882

1,908

1,943

220 0

170 0

120 0

700

200

-300

29,347

29,266

ARPOB (Rs.)

30,551

30,641

30,652

Q3FY24

Q4FY24

Q1FY25

Q2FY25

Q3FY25

Q3FY24

Q4FY24

Q1FY25

Q2FY25

Q3FY25

Diversifying revenues across hospitals

Jhansi-Orchha, 6%,

Rs. 94 mn

Greater Noida,

35%,

Rs. 582 mn

Q3 FY24 Rs. 1,668 mn

Faridabad,

Rs. 111 mn

Jhansi-

Orchha

Rs. 182 mn

Greater Noida

30%

Rs. 663 mn

Q3 FY25 Rs. 2,192 mn

Noida,

26%, Rs. 434 mn

Noida

Extension,

33%,

Rs. 559 mn

Noida,

20%

Rs. 441 mn

Noida

Extension

36%

Rs. 795 mn

• Noida Extension hospital registers robust growth at 42% YoY, contributing 36% to group’s revenue

•

In short span of being operational, Faridabad hospital has grown to contribute 5% to the group's overall revenue

Expanding high value specialties across hospitals

Diverse mix of specialties at all hospitals

17%

13%

11%

10%

7% 6% 5% 5% 5%

26%

12%

10%

Q3 FY2025

Q3 FY2024

FY2021

56%

Internal Medicine

Neurosciences

Cardiology

Pulmonology

Pediatrics

Gastroenterology

Nephrology & Urology

Oncology

General Surgery

Orthopedics, Spine & Rheumatology

Gynecology

Others

Noida extension hospital registered highest share of super specialties

Pediatrics, 3% Others, 4%

Pulmonology, 6%

Gynecology 6%

Oncology

21%

General Surgery 6%

Ortho, Spine & Rheumatology 6%

Gastroenterology 7%

Noida Ext.

Q3 FY25

Cardiology 12%

Neurosciences 9%

Internal Medicine 10%

Nephrology & Urology 10%

Operational Highlights for the quarter

Capacity Expansion •

Full payment completed against acquisitions in New Delhi (expandable capacity 300+ beds) and ~60% stake in Faridabad (~400 beds)

•

Plan to operationalize the same by Q1 FY26 • With recent bed additions, Yatharth to be

amongst top 3 leading hospital chains in North India, in terms of bed strength

Enhancing super specialties, to drive ARPOB • Oncology increases ~6x in 9M FY25, contributing 10% to Group’s revenues & ~21% to Noida Ext. revenue

•

ARPOB improves to Rs 30.6k in 9M FY25 (+8% YoY)

Noida ext. - highest ARPOB at Rs. 37.6k (+12% YoY), followed by Greater Noida at Rs. 34.6k (+21% YoY)

Faridabad Q3 ARPOB at Rs. 34.4k

Improvement in occupancy across our hospitals • Occupancy levels improves to 61% in 9M FY25,

compared to 53% in 9M FY24

•

Noida Extension and Jhansi-Orchha occupancy improves significantly to ~60% & 50% respectively in 9M FY25, compared to 42% & 20% in 9M FY24

Successful completion of QIP – raised Rs. 6,250 Mn • Despite challenging market conditions, the issue witnessed significant interest from marquee Domestic and Foreign Institutional Investors • Proceeds will be utilized towards acquisition

funding, purchase of medical equipment’s, and general corporate purposes.

Successful QIP of Rs. 6,250 mn in Dec-24

QIP Rs. 6,250 Mn

Given immense growth potential in healthcare sector, majority proceeds will be strategically deployed towards bed capacity expansion

Net Proceeds proposed to be utilized as below:

Particulars

Debt Repayment

Funding of recent Acquisitions

Purchase of Medical Equipment's

General Corporate Purposes

Total (excl. issue expenses)

Planned Outlay (Rs. Mn)

957

1,517

2,174

1,391

6,039

With fund raise, our balance sheet is well placed to further strengthen our market presence

Net Worth (Rs mn)

Net Cash (Rs mn)

18000

16000

14000

120 00

10000

80 00

60 00

40 00

2000

8,743

1,830

15,754

60 00

50 00

40 00

3000

2000

1000

-10 00

-20 00

-3000

-2,290

5 0 6 5

0 4 5 , 1

-4.8

-4.9

-5

FY23

FY24

9MFY25

FY23

FY24

9MFY25

s r o t s e v n

I e e u q r a M y b n o i t a p i c i t r a P

Update on Acquisitions Expanding footprint in New Delhi & Faridabad – made full payments for both of its recent acquisitions

Yet to commence Multi-specialty hospital

Built on approx. 2 Acre land

Proposed Capacity 400 Beds

Majority stake acquired ~ Rs. 91 crore

Located Sec-20, Faridabad, Haryana

Operationalize Q1 FY2026

❖ Strategic collaboration agreement for ~60% stake acquisition, valuing hospital at enterprise value of Rs. 152 crore.

❖ Acquisition positions Yatharth as one the largest hospital of Faridabad region in terms of bed capacity.

the

❖ Hospital's structure is complete, with plans to equip it with advanced medical equipment and offer super specialty including services, oncology treatments and robotic surgeries.

❖ Successful bidding

for MD City in Delhi through the e- Hospital auction process under the SARFAESI Act, 2002

❖ Hospital caters a large catchment of residential and institutional client base in the region

❖ Proposed acquisition will strengthen Yatharth Hospitals’ presence in the attractive market of Delhi

Established Multi-specialty hospital

Established in 2019

Expandable to 300+ Beds

Acquisition Cost ~Rs. 160 crore

Located Model Town, New Delhi

Operationalize Q1 FY2026

Other highlights during the period

Clinical Achievements

Awards & Recognitions

Successful Kidney transplant at Greater Noida by transfer through Green Corridor

Growing Fastest Hospital in Medical Travel at Value 2024! Sanjeevani and Healthcare Wellness Expo

Global &

HTI Healthcare Wellness Excellence Award Emerging for Hospital Chain in MVT (UAE)

Profit & Loss Summary

Particulars (Rs Mn)

Q3FY25

Q3FY24

Change YoY

Q2FY25

Change QoQ

9MFY25

9MFY24

Change YoY

Revenue from Operations

2,192

1,668

Medical Consumables & Pharmacy

Employee Expenses

Other Expenses

EBITDA

EBITDA Margin %

Depreciation and amortisation

Financial Cost

Other Income

Profit Before Tax (PBT)

Tax

Profit After Tax (PAT)

PAT Margin %

421

426

796

549

315

299

589

464

31%

33%

42%

35%

18%

2,178

432

415

785

546

(3%)

6,487

1,320

1,187

2,348

1,632

25.1%

27.8%

(277) bps

25.1%

(3) bps

25.2%

169

402

305

438

143

295

115%

(22%)

(8%)

(32%)

159

401

310

32%

42%

(1%)

443

108

1,232

314

918

4,926

956

852

1,784

1,334

27.1%

216

100

1,127

366

761

32%

38%

39%

32%

22%

(192) bps

105%

(28%)

(14%)

21%

13.9%

17.7%

(377) bps

14.2%

(30) bps

14.2%

15.5%

(130) bps

At a Glance

Leading Super specialty hospital in North India

87%

Hospitals*

Center of Excellence

Beds in Metros*

One-stop destination for patient needs providing all levels of healthcare services from primary to tertiary

2024 Model Town, Delhi ~300 beds

2024 Faridabad ~400 beds

2024 Gr. Faridabad 200 beds

2022 Jhansi-Orchha 305 beds

2019 Noida Extension 450 beds

2013 Noida 250 beds

2,300+

Bed Capacity*

+43%

Rs. 30,614

ARPOB (9MFY25)

61%

Occupancy (9MFY25)

Revenue (3Y CAGR)

EBITDA (3Y CAGR)

+39%

+80%

PAT (3Y CAGR)

2010 Greater Noida 400 beds

Shareholding Pattern

17.3%

9.8%

11.5%

Dec-24

61.4%

Promoters

DIIs

FIIs

Others

Key Investors

Kotak Mutual Fund

Bandhan Mutual Fund

Jupiter India

East Capital

ICICI Prudential Mutual Fund

Marval Guru

SBI Life Insurance

Citi Group

Canara HSBC Life Insurance

HSBC Global

Universal Sompo Insurance

Matthews India

Guardian Capital Partners

Grandeur Peak Funds

Carnelian Capital

Societe Generale

Upcoming Hospitals

* Including upcoming hospitals in Delhi & Faridabad

Our Journey Growing presence across regions and services

Established our first hospital in Greater Noida

Expansion of our first hospital, Greater Noida hospital, to 400 beds

Acquisition of 4th hospital - Jhansi Orchha hospital adding 305 beds, pursuant to acquisition of subsidiary, Ramraja

• Acquired 5th hospital – 200 beds in Gr. Faridabad; 6th & 7th hospital being acquired in Delhi & Faridabad

• Raised Rs. 6,250mn via QIP

2008

2010

2013

2018

2019

2022

2023

2024

Incorporation of company and commencement of operations

Established our second 250 bedded hospital, in Noida

Commencement of our third hospital, Noida Extension hospital, in May 2019, pursuant to the acquisition of subsidiary AKS in 2016

Listing on NSE & BSE

Acquisitions

Our Hospitals Built on foundation of talent, trust, technology, service and infrastructure

Diversified revenue mix across hospitals (9MFY25)

Faridabad

Jhansi-

Orchha 7%

Noida

21%

Greater Noida

32%

Noida Extension 37%

Hospitals

Year of Operation

Beds Capacity

Census Beds

No of ICU Beds

Occupancy Rate

ARPOB (₹)

ALOS

Greater Noida

Noida

Noida Extension

Jhansi - Orchha

Greater Faridabad

2010

400

330

112

65%

2013

250

215

80%

34,584

28,893

4.49

4.97

2019

450

390

125

~60%

37,608

4.29

2022

305

250

50%

13,038

3.99

2024

200

180

31%*

31,185

3.23

With upcoming hospitals in Delhi (+300 beds) & Faridabad (+400 beds), Yatharth to be amongst the leading hospital chains in North India, in terms of bed strength

4,482

40%

2,832

2,305

22%

2,139

11%

27%

1,385

1,217

1,200

552

Notes: *Given gradual ramp up in bed capacity at Faridabad, the utilization has been computed on 100 beds; All figures as per 9M FY25

Our Mature Hospitals

Greater Noida 2010 Incorporated 400 Beds; 112 ICU Beds (expandable to 600 beds)

Noida 2013 Incorporated 250 Beds; 81 ICU Beds

Noida Extension 2019 Incorporated 450 Beds; 125 ICU Beds (expandable to 700 beds)

All figures for 9M FY25 19

65% Occupancy

Rs.34,584 ARPOB

cardiology, cardiovascular and

thoracic surgery, neurology,

Provides a wide spectrum of super specialty services in the field of

neurosurgery, urology, nephrology, oncology, gastroenterology etc.

4.49 days ALOS

80% Occupancy

Rs.28,893 ARPOB

orthopedics, nephrology, urology, neurosciences, gastroenterology,

Provides services across 30 specialties, including cardiac sciences,

etc.

4.97 days ALOS

~60% Occupancy

Rs.37,608 ARPOB

4.29 days ALOS

Super specialties contribute c. 70% of overall business; continued efforts to develop this hospital as Centre of Excellence for oncology and robotic surgeries. In Mar’24, radiation oncology line was inaugurated to provide comprehensive suite of oncology treatments

Accredited by Joint Commission International (JCI) – Noida extension hospital received JCI accreditation, 1st in UP & 7th in North India to achieve this accreditation. Amongst few hospitals to get JCI accreditation in first instance.

Our New hospitals

Jhansi – Orchha 2022 Acquisition 305 Beds; 76 ICU Beds

Greater Faridabad 2024 Acquisition 200 Beds; 61 ICU Beds

50% Occupancy

Rs.13,038 ARPOB

3.99 days ALOS

31% Occupancy*

Rs.31,185 ARPOB

Hospital

Jhansi-Orchha-Gwalior

region, has

infrastructure to operate all the major super specialties

Acquired in FY22

Acquired in 2024, a newly built hospital with latest

facilities on a 1.25-acre land with empanelment with all

major insurance/TPAs in place

Operationalized on May 12, 2024, expanding Yatharth’s

3.23 days ALOS

presence in North India

Notes: *Given gradual ramp up in bed capacity at Faridabad, the utilization has been computed on 100 beds; All figures for 9M FY25

Healthcare Delivery Market in India is at Nascent stage

Indian hospital market to grow at a CAGR of 10-12% to reach INR 10tn by FY28

Globally India has one of the lowest bed density/10,000 population

(INR tn)

3.9 1.3 2.6

FY19

6.3

1.8

4.5

FY24E

IPD

OPD

9.4-9.8

2.6

7.2

FY28P

World Average: 33

Hospitals constitute the largest share of the healthcare market in India

Pvt. hospitals share is expected to increase 70% by FY28P

Hospitals

Domestic Pharmaceuticals

FY24 E

20%

62%

Diagnostics

Medical Devices

33%

30%

FY24 E

FY28 P

67%

70%

Source: CRISIL Report

North India - Underserved market with huge growth potential

North India hospital market is expected to grow at a CAGR of 12-14%...

…Growing at a faster rate than the overall industry

(INR tn)

1.1-1.5

1.9-2.0

FY19

FY24E

FY28P

3.1-3.2

(INR tn)

3.9

22.5-23.5%

11.5-12.5%

35-36%

29-30%

FY19

9-11%

10-12%

9-11%

10-12%

6.3

22-24%

10.5-12.5%

34-36%

10-12%

11-13%

10-12%

9-11%

9.4-9.8

22-25%

10-13%

32-35%

29.5-31.5%

12-14%

30.5-33.5%

FY24E

FY28P

North

South

East

West

Low concentration of private chains in North India

Bed density of Delhi-NCR is below WHO recommendations

Total hospital beds (‘000)

20-21

6-6.5

110-115

295-300

64-66

44-46

40-42

Beds of private chains as a % of total beds (2022)

0-1%

1-2%

2-3%

2.5-3.5%

4.5-5.5%

14-15%

18-19%

P H

h r a g d n a h C

n a h t s a a R

P U

b a n u P

Source: CRISIL Report

h e D

a n a y r a H

Total beds per 10,000 population

WHO Recommendation

a b m u M

d a b a r e d y H

a n n e h C

u r u a g n e B

R C N

h e D

Proximity to international airports to fuel medical tourism

India’s medical tourism industry has been growing

~45% of the international patients travel to Delhi-NCR

40%

5.0

4.3

6.4

22%

7.0

2.3

11%

27%

4.8

3.0

1.8

2015

2016

2017

2018

2019

2020

2021

2022

Model Town, Delhi (~24 km from IGI)

Faridabad (~33 km from IGI, ~47 km from Jewar)

Indira Gandhi Int. Airport

Noida Extension (~42 km from IGI; 58 km from Jewar)

Noida (~33 km from IGI; ~56 km from Jewar)

Greater Noida (~42 km from Jewar)

Gr. Faridabad (~38 km from IGI, ~40 km from Jewar)

Noida Int. Airport (Jewar)

India offers comparatively lower treatment costs

Yatharth hospital to benefit from medical tourism

Procedure Cost ($)

India

Korea

Singapore

Thailand

Average Global Cost

India Discount %

Hip Replacement

Knee Replacement

Heart Bypass

Angioplasty

Heart Valve Replacement

7,000

6,200

5,200

3,300

50,000

14,120

12,000

7,879

21,000

50,000

19,800

13,000

12,297

23,774

144,000

28,900

18,500

57,000

15,200

13,000

5,500

170,000

43,500

12,500

15,121

3,788

21,212

3,636

51,630

22,247

61,803

3,034

Dental Implant

1,000

2,800

4,200

1,500

2 3

Source: Industry reports

-67%

-74%

-90%

-85%

-91%

-67%

Modern infrastructure and facilities

Availability of senior clinical talent

State-of-the- art medical equipment's

High connectivity across North India

Reputed for tertiary care

Yatharth is well positioned in most of the levers

Yatharth

Apollo

Max

Fortis

KIMS

Jupiter

Strategic Levers to improve competence

✓ On track to expand bed

capacity to ~3,000 by FY28 ✓ Increasing share of super

specialties & introduction of oncology and robotics, driving ARPOB improvement

✓ Focus to grow self payors, private insurance and international business to improve payor mix

No of beds

Beds in Metros %

Revenue 3Y CAGR

EBITDA Margins

RoCE

ARPOB

Payor Mix

High Competence

Medium Competence

Low Competence

Core strategies driving growth

Optimizing Infrastructure Enhancing occupancy and ARPOB across our hospitals

Capacity Addition Greenfield and brownfield expansion

Leverage Technology Advanced and high-end medical equipment and technology

Clinical Expertise Attracting best talent to drive super specialties

Optimizing Infrastructure

Capacity Expansion

Leverage Technology

Clinical Expertise

Optimizing existing infrastructure

Mature hospitals

New hospitals

Total

42%

50%

55%

45%

63%

54%

66%

61%

45%

23%

FY21

FY22

FY23

FY24

9MFY25

) % ( y c n a p u c c O

) s R ( B O P R A

21,287

23,511

26,886

26,538

29,646

28,571

34,124

30,614

Optimized scheduling

FY21

FY22

2 6

Optimizing Infrastructure

17,692

17,429

16,192

FY23

FY24

9MFY25

Expand Services

Improve customer service

Diversifying specialties

Our 5-fold approach to optimize existing infra

Enhanced care coordination

Capacity addition - greenfield and brownfield expansion

Capacity addition trend and roadmap ahead

Operational Beds

New bed addition

Planned bed addition

Target bed capacity

May-24

Operationalize by Q1 FY26

~300

Operationalize by Q1 FY26

~200-300

450*

~400

~3,000

Apr-22

May-19

*Bed capacity to be expanded by 200 and 250 beds at Greater Noida & Noida Extension in 24-30 months respectively.

Capacity Expansion

Advanced and high-end medical equipment and technology

• Hospitals are equipped with machines and devices with sophisticated technology •

Strive to introduce medical technology and state-of-the-art equipment

Complex procedures

Presence in Hospitals

No. of procedures performed till date

Kidney, Liver & Bone Marrow Transplant

Robotic Surgeries – DaVinci, Mako & Cuvis

Radiation Oncology

Noida Ext & Greater Noida

Noida Ext, Greater Noida & Faridabad

Noida Extension

200+

600+

1,100+

Catheterization Laboratory Computerized Tomography Scan (CT Scan)

• • • Magnetic Resonance Imaging (MRI) •

Imaging equipment - Mammography, Advanced EEG, Nerve conduction velocity, advanced surgical equipment etc.

Diagnostic Equipment

Certifications

• We have NABH accreditation for all leading

hospitals. We are also in advances stages of getting NABH accreditation for Faridabad and Jhansi hospital.

• We have NABL certification for our leading

hospitals.

• Well-equipped modular and other operation theatres with three stage air filtration and laminar flow Operating microscopes, image intensifiers, and laparoscopic equipment

•

Operation Theatres

•

Critical care units are equipped with patient monitoring devices, ventilators and dedicated isolation rooms Facilities for haemodialysis, sustained low- efficiency dialysis, endoscopy and bronchoscopy are available 24x7 by the bedside

Critical care Equipment

Leverage Technology

Attracting best talent to drive super specialties

Integrating talent from well-established allied workforce

First mover advantage in building out network across Tier II/III cities

Strategic initiatives aimed to ease attrition

❑ Introduced DNB program across 8

specialties in 2 of the hospitals

❑ DNB program to reduce attrition of

Resident Medical Doctors

❑ Total 30 resident doctors have joined the

DNB program till date

❑ Keep

staff

global developments concerning the health sector

abreast with

Stronger local connect with people

Promoters being doctors, have better connect with doctors

❑ Provide better doctor visibility amongst the potential patients through marketing and awareness campaigns

Clinical Expertise

Proven record of consistent financial performance (1/2)

Revenue (Rs mn)

EBITDA (Rs mn) & EBITDA%

6,705

6,487

5,203

4,926

4,009

2,287

29.3%

27.6%

25.7%

26.8%

27.1%

25.2%

1,108

1,338

670

1,799

1,334

1,632

2300 2295 2290 2285 2265227022752280 2260 2255 2250 2245 2240 2235 220522102215222022252230

2200

2095210 0210 5211021152120212521302135214 0214 5215 0215 5216 0216 521702175218 0218 5219 0219 5

2090 2085 2080 2075 20652070 2060 2055 2050 2045 2040 2035 2030 2025 2020 200520102015 2000 1995 1990 1985 1980 196519701975 1960 1955 1950 1945 1940 1935 1930 1925 1920 190519101915 1900 1895 1890 1885 1880 186518701875 1860 1855 1850 1845 1840 1835 1830 1825 1820 180518101815 1800 1780178517901795 176 517701775

1695170017051710171517201725173017351740174517501755176 0

1690 1685 1680 1675 16651670 1660 1655 1650 1645 1640 1635 1630 1625 1620 160516101615 1600 1595 1590 1585 1580 156515701575 1560 1555 1550 1545 1540 1535 1530 1525 1520 150515101515 1500 1495 1490 1485 1480 146514701475 1460 1455 1450 1445 1440 1435 1430 1425 1420 140514101415 1400 1395 1390 1385 1365137013751380 1360 1355 1350 1345 1340 1335 130513101315132013251330 1300 129 5 129 0 128 5 128 0 126 512701275 126 0 125 5 125 0 124 5 120 5121012151220122512301235124 0

120 0

1095110 0110 5111011151120112511301135114 0114 5115 0115 5116 0116 511701175118 0118 5119 0119 5

1090 1085 1080 106510701075 1060 1055 1050 1045 1040 1035 1030 1025 1020 100510101015 1000

0510152025303540455055606570758085909510010511011512012513013514014515015516016517017518018519019520020521021522022523023524024525025526026527027528028529029530030531031532032533033534034535035536036537037538038539039540 040 541041542042543043544 044 545 045 546 046 547047548 048 549 049 550 050 551051552052553053554 054 555 055 556 056 557057558 058 559 059 560 060 561061562062563063564 064 565 065 566 066 567067568 068 569 069 570070571071572072573073574074575075576076577077578078579079580 080 581081582082583083584 084 585 085 586 086 587087588 088 589 089 590 090 591091592092593093594 094 595 095 596 096 597097598 098 599 099 5

FY21

FY22

FY23

FY24

9MFY24

9MFY25

FY21

FY22

FY23

FY24

9MFY24

9MFY25

Finance Cost (Rs mn)

188

215

214

FY21

FY22

FY23

FY24

9MFY24

9MFY25

0.21

0.2

0.19

1800

1600

1400

120 0

1000

80 0

60 0

40 0

200

8.6%

196

FY21

PAT (Rs mn) & PAT%

12.6%

11.0%

442

658

17.1%

1,145

15.5%

14.2%

761

918

FY22

FY23

FY24

9MFY24

9MFY25

300

250

200

150

100

3 0

30%

29%

28%

27%

26%

25%

24%

23%

22%

21%

20%

19%

18%

17%

16%

15%

14%

13%

12%

11%

10%

21%

20%

19%

18%

17%

16%

15%

14%

13%

12%

11%

10%

Proven record of consistent financial performance (2/2)

Return on capital employed (%)

Return on equity (%)

27%

28%

29%

45%

44%

23%

27%

22%

14%

FY22

FY23

FY24

H1FY25

FY21

FY22

FY23

FY24

H1FY25

18%

FY21

Gross Block (Rs mn)

Capex per bed

3.91

3.72

3.07

3.90

4.40

6,260

7,062

3,374

4,090

4,319

FY21

FY22

FY23

FY24

H1FY25

750 0

650 0

550 0

450 0

350 0

250 0

150 0

500

-500

130

125

120

115

110

105

100

4.5 0

4.0 0

3.5 0

3.0 0

2.5 0

2.0 0

1.5 0

1.0 0

0.5 0

0.0 0

FY21

Net Working Capital Days

112

104

FY22

FY23

FY24

H1FY25

Consistent performance across operational parameters

Occupancy (%)

42%

50%

45%

54%

53%

61%

IPD/OPD Revenue (in ‘000s)

IPD Revenue

OPD Revenue

5,203

684

4,519

4,009

546

3,464

2,287

227 2,060

6,705

819

5,886

6,487

755

5,732

4,928

603

4,324

FY21

FY22

FY23

FY24

9MFY24

9MFY25

FY21

FY22

FY23

FY24

9MFY24

9MFY25

ARPOB (Rs.)

ALOS (days)

21,287

23,511

26,538

28,571

28,328

30,614

FY21

FY22

FY23

FY24

9MFY24

9MFY25

FY21

FY22

FY23

FY24

9MFY24

9MFY25

5.03

5.20

4.32

4.78

4.75

4.38

Awards and Accreditations

2020

2021

2022

2023

2024

➢ Awarded

1st

➢ Covid Thank You award

➢ 5-star

grading

➢ Awarded

Swachhta Ranking (for

by Niva Bupa

Infomerics Analysts &

Samman

Ratan

Dainik

➢ Accreditation from NABH

Research

for

our

Jagran Inext

to the Noida Extension

hospitals

located

➢ Accreditation

(ISO

Hospital

Greater Noida

15189:2012) from NABL for

medical testing to the

Noida Extension Hospital

quarter ended Sep 2019)

in Swachh Survekshan

League 2020 by Noida

Authority

➢ Recognized as Emerging

Hospital Chain in Delhi

NCR by Medico Trip India

➢ Accreditation

(ISO

15189:2012) from NABL for

molecular

testing

(RTPCR-Covid 19) for the

Noida Extension Hospital

➢ Awarded Best Brand for

Excellence in Healthcare

at Economic Times (ET)

Edge

Best

Brands

Conclave, for consistent

innovation

and

customer-centricity

➢ Noida extension hospital

accredited

Joint

Commission

International

(JCI) –

being 1st in UP & 7th in

North India to get this

accreditation

Experienced board and leadership team

Dr. Ajay Kumar Tyagi Chairman & Whole-time Director

17+ yrs of experience Bachelor of medicine, surgery, and diploma in orthopaedics

Dr. Kapil Kumar Managing Director

17+ yrs of experience Bachelor of medicine, surgery, and master of orthopedic surgery, Magister chirurgie in orthopedics

Yatharth Tyagi Whole-time Director

Bachelor’s in business mgmt from Leeds Beckett University Master’s of science in International Health Management from Imperial College, London

Promila Bhardwaj Independent Director

35+ yrs of experience Bachelor of arts, Master’s of arts in English, philosophy in social sciences and diploma in public administration

Mukesh Sharma Independent Director

35+ yrs of experience Bachelor’s in science agriculture & animal husbandry Master’s in business administration Post graduate diploma in labour law & welfare, & personnel mgmt Bachelor’s of law

Sanjeev Upadhyaya Independent Director

20+ yrs of experience Bachelor’s in medicine, surgery Doctor of medicine in community medicine

Amit Kumar Singh Chief Executive Officer

20+ yrs of exp

Nitin Gupta COO & President - Finance

Pankaj Prabhakar Chief Financial Officer

Neeraj Vinayak Head, Strategy & Investor Relations

Sonu Goyal Group Finance Controller

21+ yrs of experience

20+ yrs of exp

19+ yrs of experience

16+ yrs of experience

s r o t c e r i D

f o d r a o B

s P M S / s P M K

Thank You

Yatharth Hospital & Trauma Care Services Ltd

Investor Relations Contact

Mr. Neeraj Vinayak, Head – Strategy and Investor Relations

investor.relations@yatharthhospitals.com

CIN: L85110DL2008PLC174706

www.yatharthhospitals.com

← All Transcripts YATHARTH Stock Page →

Yatharth Hospital & Trauma Care Services Limited has informed the Exchange about Investor Presentation

Market Movers